Treatment of Experimental Neuroblastoma with Angiogenic Inhibitors

Neuroblastoma is a childhood cancer which arises from neuroblasts in the peripheral nervous system. Neuroblastoma show substantial heterogeneity regarding location, responsiveness to treatment and prognosis. Due to the fact current therapy requires drugs with likelihood of severe negative effects in the growing child, there’s a clinical requirement of more efficient and less toxic treatment strategies. Angiogenesis, the development of new blood vessels, is crucial for tumor progression. Specific inhibition of tumor-induced angiogenesis should prohibit expansion of most solid tumors and thereby offer a new treatment strategy. The objective of this research was to look into the effects of angiogenic inhibition in experimental neuroblastoma in mice…


Childhood cancer
Angiogenic factors
Vascular Endothelial Growth Factor
VEGF receptors
Platelet Derived Growth Factor
PDGF receptors
Stem cell factor (SCF) and its receptor c-KIT
FLT3 ligand (FL) and its receptor FLT3
Therapeutic interference with VEGF/PDGF-induced angiogenesis
Angiogenic inhibitors and chemotherapy
Present investigation
Material and methods
Neuroblastoma cells
Administration of drugs
Perfusion fixation and autopsy
Blood analyses
Tissue analyses
In-situ hybridization
Stereological quantification
Statistical methods
Result and discussion
Importance of Vascular Endothelial Growth Factor A in the Progression of Experimental Neuroblastoma (Paper I)
The Selective Class III/V Receptor Tyrosine Kinase Inhibitor
SU11657 Inhibits Tumor Growth and Angiogenesis in Experimental Neuroblastoma (Paper II)
CHS 828 Inhibits Neuroblastoma Growth in Vivo Alone and in
Combination with Antiangiogenic Drugs (Paper III)
The Bisphosphonate Zoledronic acid Reduces Experimental
Neuroblastoma Growth by Interfering with Tumor Angiogenesis
(Paper IV)

Source: Uppsala University Library

Download URL 2: Visit Now

Leave a Comment